Vanda Pharmaceuticals' Late-Stage Study of VQW-765 to Treat Acute Anxiety Fails to Meet Primary Endpoint
Phase 3negativeVQW-765Negative
AI Analysis
Summary
Vanda Pharmaceuticals' late-stage study of VQW-765 for acute anxiety failed to meet its primary endpoint. This represents a significant setback for the company's anxiety treatment program.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Late-stage study failed to meet primary endpoint
Importance:8/10
Sentiment:
-0.95
clinical_trial_failurephase_3negative_dataanxietydrug_development
Related Companies
Read the original article
Published by yahoo_finance on October 14, 2026 9:35 PM